CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 80 enrolled
Drug / intervention
Liposomal bupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02959996
NCT02959996Phase 3Completed

Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain

Massachusetts General Hospital·interventional·Posted Nov 9, 2016·Updated Aug 27, 2018

In Brief

A Phase 3 clinical trial evaluating Liposomal bupivacaine and Placebo for Pain, Postoperative. Completed, enrolled 80 participants across 1 site.

Detailed Summary

This is a randomized controlled trial to test whether the use of liposomal bupivacaine at the time of cesarean delivery may decrease post-operative pain scores.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 9, 2016
Enrollment StartMar 8, 2017
Primary CompletionSep 25, 2017
Study CompletionNov 3, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 9.6 years ago

Interventions

Liposomal bupivacainedrug

liposomal bupivacaine injection in the Pfannenstiel incision

Placebodrug

placebo injection in the Pfannenstiel incision